Markets

Recursion Announces Sanofi Option Of First Immunology Drug Candidate, Triggering $10M Milestone Payment And Potential Phase 1 Trials In 2027

Oct 15, 2026 · 08:42 AM ET· updated 1h ago

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development CandidateOn October 15, 2026, Recursion announced that Sanofi has optioned the first development candidate from the two companies’

Why It Matters

Sanofi chose to test Recursion's new immunology drug candidate. This shows the partnership is moving forward and Recursion gets money now.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

RXRX3.94

+0.20 (+5.35%)

SNY40.65

+0.88 (+2.20%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.